Ir.alexionpharm.com

Ir Alexion Pharm. Inc. business for stockholders, potential investors, and financial analysts.

Never miss Ir.alexionpharm.com updates: Start reading the news feed of Ir Alexion Pharm right away! This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Ir.alexionpharm.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Ir Alexion Pharm

Subscribe to related news

Alexion Pharmaceuticals Upgraded to Outperform at Zacks (ALXN)
via americanbankingnews

Alexion Pharmaceuticals (NASDAQ:ALXN) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Friday, AnalystRatingsNetwork reports. The firm currently has a $189.00 price target on the...
Post Market News: Boeing, Dell, United Parcel, Disney, Yelp, Edwards
via valuewalk

Post Market Update Stocks that traded actively in U.S. markets on Friday include: The Boeing Company (NYSE:BA), Dell Inc. (NASDAQ:DELL), United Parcel Service, Inc. (NYSE:UPS), Yelp Inc (NYSE:YELP), Edwards Lifesciences Corp (NYSE:EW), Medtronic, Inc...
FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myast...
via mda

NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) to extend the indication...
Alphamab Appoints New Senior Executives in Operation and Business Development
via military-technologies

SUZHOU, China--(satPRNews.com)--Suzhou Alphamab Co., Ltd. announced today the appointment of Claudia Lin, Ph.D. as General Manager of Alphamab (Jiangsu) Biopharmaceuticals Co., Ltd., a newly established subsidiary with an initial funding of $300 million...
Nektar Therapeutics Receives a Buy from Brean Capital
via analystratings

Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Nektar Therapeutics (NASDAQ: NKTR) today and set a price target of $16. The company’s shares closed yesterday at $10.78. Aschoff wrote, “Nektar hosted an R&D Day event yesterday focusing...

Ir.alexionpharm.com popular pages

Investor Relations - Alexion Pharmaceuticals, Inc.

The Investor Relations website contains information about Alexion Pharmaceuticals, Inc. business for stockholders, potential investors, and financial analysts.
Shareholder Tools - Alexion Pharmaceuticals, Inc.

The Investor Relations website contains information about Alexion Pharmaceuticals, Inc. business for stockholders, potential investors, and financial analysts....

Alexion to Present at Investor Conferences (NASDAQ:ALXN)

CHESHIRE, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Vikas Sinha, Chief Financial Officer of Alexion Pharmaceuticals, will present ...